Acadia Pharmaceuticals (ACAD) PT Raised to $38 at RBC Capital

RBC Capital analyst Gregory Renza raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $38.00 (from $26.00) while maintaining an Outperform rating.

The analyst commented: "ACAD represents a solid commercial-stage story with an emerging pipeline, with a meaningful recent Nuplazid IP win providing a high likelihood of cash flow sustainability and commercial tailwinds of late suggesting some continued Nuplazid growth and Daybue stabilization prospects. Maturing commercial franchises, exposure to macro/policy issues (IRA, MFN), and higher risk to the next pipeline catalyst ('101 for PWS) add some complexity to the setup, but with the scarcity value of $1B + annual revenue from existing products now likely sustainable well into the next decade and at a <$4B cap, stock looks fundamentally undervalued and any pipeline contribution is likely all upside."

You May Also Be Interested In

• SpaceX (SPCX) gains nearly 6% as traders follow the money
• Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
• argenx SE (ARGX) PT Raised to $1,150 at Wedbush